G Ergometrine 200 mcg/ml Injection

Postpartum and post-abortion bleeding, 3rd stage of labour, Uterine bleeding, Postpartum haemorrhage Pregnancy, 1st and 2nd stage of labour, patients with preeclampsia, eclampsia or threatened spontaneous abortion; porphyria.

Drugs acting on the Uterus

Ergometrine causes contraction of the uterine muscle. At low doses, there is an increase in frequency and amplitude of contractions while at higher doses, the basal tone of the uterus is increased. Ergometrine also causes vasoconstriction of peripheral and cerebral vessels.

Adult Dose: Pospartum or Postabortion Hemorrhage Oral: 0.2-0.4 mg PO q6-12hr PRN for 48 hr or until danger of uterine atony has passed; no more than 1 week Parental 0.2 mg IM; may repeat in 2-4hr; not to exceed 5 doses total Give IV only in emergency because of potential for HTN & CVA Give over >1 minute & monitor BP

Halothane causes relaxation of uterine muscle and may interfere with ergometrine action. Enhanced uterotonic effect with prostaglandins and oxytocin. Concurrent admin with CYP3A4 inhibitors may lead to vasospasm, cerebral ischaemia and/or ischaemia of extremities. Potentially Fatal: Enhanced vasoconstrictive effects with sympathomimetics and other vasoconstrictors.

Pregnancy, 1st and 2nd stage of labour, patients with preeclampsia, eclampsia or threatened spontaneous abortion; porphyria.

Nausea, vomiting, abdominal pain, diarrhoea; headache, dizziness; tinnitus; chest pain, palpitation, bradycardia, transient hypertension and other cardiac arrhythmias; dyspnoea, sometimes rashes, shock. Potentially Fatal: MI, pulmonary oedema.

Pregnancy Category X. Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

Precaution: Breech and abnormal foetal presentation; hypertension; chronic anaemia; hepatic, renal, respiratory or cardiac impairment; toxemia; lactation; hypocalcaemia. Monitor BP, pulse and uterine response. Lactation: excreted in milk; adverse effect on the nursing infant; may inhibit lactation; use not recommended

Symptoms include peripheral vasoconstriction, encephalopathy, convulsions, respiratory failure, acute renal failure and temporary lactose intolerance. Treatment is supportive.

Intramuscular: Active management of the third stage of labour: Refrigerate at 2-8°C.Intravenous: Refrigerate at 2-8°C.Oral: Store below 25°C.

Drugs acting on the Uterus

Ergometrine causes contraction of the uterine muscle. At low doses, there is an increase in frequency and amplitude of contractions while at higher doses, the basal tone of the uterus is increased. Ergometrine also causes vasoconstriction of peripheral and cerebral vessels.

Pregnancy Category X. Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

Related Medicines

Save Medicine to Collection

G Ergometrine 200 mcg/ml

Create New Collection